The United States leads global medtech
Most of the top medical technology companies come from the United States. Some are only divisions of larger companies, like global leader Johnson & Johnson Medical Devices & Diagnostics, or General Electric Healthcare. In 2019, Johnson & Johnson made nearly 26 billion U.S. dollars through its medtech division, and thus was the top U.S.-based company.Leading segments in medical technology
The strongest businesses within the medtech industry are in vitro diagnostics (IVD), cardiology, diagnostic imaging, and orthopedics. In vitro diagnostics currently generate some 53 billion U.S. dollars globally, but are forecasted to reach some 80 billion dollars by 2024. Swiss-based company Roche is the global top manufacturer, generating over 10 billion U.S. dollars in worldwide IVD revenue. However, it is expected that Roche's share of the global in vitro diagnostics market will decrease from almost 20 percent in 2017 to around 17.8 percent in 2024.Robotics: the state of the art segment
Robot-assisted surgery and surgical robots clearly show how far development in medical technology has come. The implementation of artificial intelligence (AI) in this sector is crucial, showing huge potential for more precise and cost efficient surgical procedures. The global market for surgical robots is estimated to reach nearly 13 billion U.S. dollars in 2025. Recent surveys show that large parts of Americans – especially younger generations - already have confidence in surgical robots and would prefer them.Crises and their impact on medtech
Although medtech revenues kept increasing over the last years, the the global financial crisis of 2007-2008 had a negative impact on the industry. This can be shown by reference to the number of IPOs, which after the crisis was distinctly lower than before it. However, starting with 2013, a strong upward trend is visible throughout the industry's IPO activity. How far the coronavirus pandemic will have an affect on medical technology IPOs, M&As, and funding in total 2020, is still to be seen.
